Moreover, HER2-amplified breast cancers display increased sensitivity to certain chemotherapeutic agents, such as doxorubicin, increased resistance to certain hormonal agents, such as tamoxifen, and increased propensity to metastasize to the brain, lungs, and liver [66,67]. This evidence concerns the gene ERBB2 and breast carcinoma.